- A multi-institutional team of researchers, including those at Dana-Farber, have identified a new molecular pathway responsible for causing heart failure and showed that a first-in-class prototype drug, JQ1, blocks this pathway to protect the heart from damage.
- U.S. News & World Report’s Best Hospitals guide has ranked Dana-Farber/Brigham and Women’s Cancer Center the top cancer center in New England for the 13th straight year and fifth overall in the country.
- New research shows that although women who survived childhood cancer face an increased risk of infertility, nearly two-thirds of those who tried unsuccessfully to become pregnant for at least a year eventually conceived.
Tags: ChildhoodCancer, Survivorship
- Dana-Farber has been named a “Leader in LGBT Healthcare Equality” in the Healthcare Equality Index 2013, an annual survey by the Human Rights Campaign Foundation, the educational arm of the country’s largest lesbian, gay, bisexual and transgender organization.
Tags: Honors, PatientSupport
- A novel pairing of two cancer drug types showed promising activity and had manageable toxicities, according to a first-of-its-kind clinical trial led by scientists at Dana-Farber Cancer Institute.
Tags: BreastCancer, OvarianCancer, GynecologicCancers
- Dana-Farber Cancer Institute scientists provide the first statistically-based guidelines for determining whether stem cell transplant is appropriate for patients older than 60 with myelodysplastic syndromes (MDS)
Tags: StemCellTransplant, Leukemia
- Dana-Farber has officially opened its new communications studio, which includes an upgraded on-site HD TV broadcast camera system.
- The Obama Administration recognizes John Quackenbush, PhD, of Dana-Farber, as an Open Science Champion of Change for his contributions to the larger research community.
- Dana-Farber researchers find many men with low-risk, localized prostate cancers can safely choose observation instead of undergoing immediate treatment and have a better quality of life while reducing health care costs.
Tags: ProstateCancer, PopulationScience
- A new Dana-Farber study shows a “big picture” view of an overactive B cell receptor (BCR) signaling pathway that drives about one-third of Diffuse Large B-Cell Lymphomas, which could lead to more promising genetic targets for drug development.
Showing 31-40 of 445 items